Myriad Genetics (NASDAQ:MYGN) reports upbeat Q3 2026, stock jumps 10.7%
Myriad Genetics reported Q3 2026 revenue of $202.7M, beating estimates by 6.1%, and adjusted EPS of -$0.11, beating estimates by 44.9%. The company raised its full-year revenue guidance to $785M. Despite improvements, operating margin and free cash flow declined.
How this was made
The 30-second read
Why it matters
Earnings beat and guidance raise are likely to drive short‑term buying pressure.
Market read
Earnings surprise provides a clear catalyst for MYGN traders.
What to watch
Free cash flow is still strongly negative, and operating margin worsened year‑on‑year.
Background
Myriad Genetics reported Q3 2026 results, beating estimates and slightly raising its full‑year revenue outlook.
Ticker impact
Q3 2026 earnings beat revenue and EPS estimates and raised full-year revenue guidance.
upward pressure as market prices in the beat and raised guidance
Both revenue and EPS beat consensus and guidance was increased, which typically drives buying.
Market effects
Improves outlook for the genetic testing sector as MYGN shows resilience.
US biotech stocks may see modest gains following the beat.
Limited to investors tracking US-listed biotech earnings.
Counterpoint
The beat may be temporary; underlying cash flow remains negative and margins are deteriorating.
Key entities
- companyMyriad Genetics
NASDAQ‑listed genetic testing firm.
